Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 3;5(3):280-284.
doi: 10.21873/cdp.10440. eCollection 2025 May-Jun.

Perspective on an Innovative Curative Strategy for Peritoneal Metastasis Involving Peritonectomy, Hyperthermic Intraperitoneal Chemotherapy, and Adjuvant Chemotherapy Identified as Effective in the Histoculture Drug Response Assay (HDRA)

Yohei Asano  1   2   3 , Yutaka Yonemura  4 , Chihiro Hozumi  5 , Kohei Mizuta  1   2 , Byung Mo Kang  1   2 , Jin Soo Kim  1   2 , Norio Yamamoto  3 , Katsuhiro Hayashi  3 , Hiroaki Kimura  3 , Shinji Miwa  3 , Kentaro Igarashi  3 , Takashi Higuchi  3 , Sei Morinaga  3 , Hiroyuki Tsuchiya  3 , Satoru Demura  3 , Robert M Hoffman  1   2
Affiliations

Perspective on an Innovative Curative Strategy for Peritoneal Metastasis Involving Peritonectomy, Hyperthermic Intraperitoneal Chemotherapy, and Adjuvant Chemotherapy Identified as Effective in the Histoculture Drug Response Assay (HDRA)

Yohei Asano et al. Cancer Diagn Progn. .

Abstract

Background/aim: Peritoneal carcinomatosis is the end stage for patients with gastrointestinal cancer, with survival ranging between 2 and 9 months. Pancreatic acinar cell carcinoma (PACC) is rare and can result in peritoneal metastases. The efficacy of chemotherapy for patients with PACC is unknown, and a systemic treatment strategy has not been established. The aim of the present perspective is to discuss a potential curative strategy combining surgery, heated intraperitoneal chemotherapy (HIPEC), and the histoculture drug response assay (HDRA) to identify effective adjuvant chemotherapy for PACC with peritoneal metastases, based on a published case report.

Case report: A 31-year-old man with a 20 cm epigastric mass, diagnosed as PACC, had curative-intent resection of a tumor on the distal stomach and pancreas tail. The patient recurred after four courses of adjuvant oral S-1 treatment. Laparotomy demonstrated peritoneal metastases with a peritoneal cancer index of 18. Ascites or other cancer cells in the peritoneal wash were not found. Peritonectomy, combined with HIPEC with gemcitabine and docetaxel, was performed intraoperatively. Postoperative 3-dimensional histoculture of fragments of the resected tumor with drug response testing with the histoculture drug response assay (HDRA) showed gemcitabine had the highest tumor inhibitory rate (70%) among six drugs tested. Based on the HDRA results, the patient was treated with adjuvant systemic gemcitabine chemotherapy. The patient did not have a recurrence within 18 months after surgery.

Conclusion: The present innovative treatment of PACC with peritoneal metastases used laparotomy to determine the extent of peritoneal metastases, peritonectomy to attempt to completely remove the tumor, HIPEC for intraoperative hyperthermic-chemotherapy, and the HDRA to determine the most effective drug for adjuvant chemotherapy. These procedures can be individualized for each patient's cancer, and the HDRA is most critical for individualization.

Keywords: HDRA; HIPEC; Peritoneal metastasis; adjuvant chemotherapy; cure; gemcitabine; histoculture drug response assay; hyperthermic intraperitoneal chemotherapy; pancreatic acinar cell carcinoma; peritonectomy.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no competing interests regarding this work.

Figures

Figure 1
Figure 1
Effective treatment of peritoneal metastatic cancer.
See this image and copyright information in PMC

References

    1. Yonemura Y, Ishibashi H, Fujita T, Liu Y, Wakama S, Sako S, Kitai T, Katayama K, Kamada Y, Taniguchi K, Fujimoto D, Kajiwara J, Hoffman RM. Pancreatic acinar cell carcinoma with peritoneal recurrence treated with peritonectomy and intraoperative hyperthermic intraperitoneal chemotherapy-a case report. Jpn. J Cancer Chemother. 2023;50(13):1931–1933. - PubMed
    1. Ikezawa K, Urabe M, Kai Y, Takada R, Akita H, Nagata S, Ohkawa K. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol. 2024;54(3):271–281. doi: 10.1093/jjco/hyad176. - DOI - PMC - PubMed
    1. Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic review and case series report of acinar cell carcinoma of the pancreas. Cancer Control. 2016;23(4):446–454. doi: 10.1177/107327481602300417. - DOI - PubMed
    1. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from pancreatic cancer registry of Japan pancreas society. Pancreas. 2007;35(1):42–46. doi: 10.1097/mpa.0b013e31804bfbd3. - DOI - PubMed
    1. Satake T, Morizane C, Rikitake R, Higashi T, Okusaka T, Kawai A. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57(11):890–901. doi: 10.1007/s00535-022-01920-5. - DOI - PMC - PubMed

LinkOut - more resources